We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 2,115

No Nexus For Novartis Gilenya Patent
  • Foley & Lardner LLP
  • USA
  • April 25 2017

In Novartis AG v. Torrent Pharmaceuticals Ltd., the Federal Circuit affirmed the decision of the USPTO Patent Trial and Appeal Board (PTAB


How to Avoid Costly Beneficiary Designation Litigation - Helpful Hints for All Benefit Plans
  • Foley & Lardner LLP
  • USA
  • April 10 2017

When administering an employee benefits plan, it is critically important to provide clear and specific instructions as to how a participant can


Former UBS Executive Claims Company Fired him for FINRA Testimony
  • Foley & Lardner LLP
  • USA
  • April 18 2017

UBS Financial Services, Inc. has been served with a whistleblower lawsuit by former employee Craig D. Price, who was a Florida-based wealth adviser


“Horizontal Shareholding:” Is Oligopoly Pricing a Symptom or the Disease?
  • Foley & Lardner LLP
  • USA
  • March 30 2017

In 2008, the U.S. Department of Justice’s Antitrust Division (“DOJ”) let Delta Air Lines merge with Northwest Airlines.1 Two years later


Supreme Court Passes on Opportunity to Review Attempted Whistleblower’s Petition
  • Foley & Lardner LLP
  • USA
  • April 18 2017

On March 20, 2017, the U.S. Supreme Court declined the invitation to review a former Morgan Stanley employee's claims that he is entitled to


Making Employees Watch the Clock Can be Good for Employers
  • Foley & Lardner LLP
  • USA
  • April 17 2017

A few months ago, we reminded our readers about the need to maintain accurate time records for non-exempt employees.This consideration is especially


Angiomax Patents Limited To Example
  • Foley & Lardner LLP
  • USA
  • April 18 2017

In The Medicines Co. v. Mylan, Inc., the Federal Circuit construed composition claims of two Angiomax patents as requiring the recited “batches” to


Ninth Circuit Rules that Dodd-Frank Act Protects Non-SEC Whistleblowers
  • Foley & Lardner LLP
  • USA
  • April 18 2017

On March 8, 2017, a divided panel of the Ninth Circuit Court of Appeals held that the Dodd-Frank Act's anti-retaliation protections extend to


Private Arbitration Agreements which Prohibit Public Injunctive Relief Violate Public Policy and are Unenforceable Under California Law
  • Foley & Lardner LLP
  • USA
  • April 12 2017

In an April 5, 2017 unanimous opinion, the California Supreme Court (the “Court”) held that private arbitration agreements which prohibit public


Third Circuit Permits Former In-House Attorney to Pursue Dodd-Frank Act Claims
  • Foley & Lardner LLP
  • USA
  • April 18 2017

The Third Circuit recently held that the trial court should not have dismissed an ex-Vanguard Group, Inc. in-house attorney's wrongful termination